Leukocyte apoptosis

Leukocyte apoptosis is the programmed cell death of white blood cells, a fundamental biological process critical for maintaining immune system homeostasis and resolving inflammation. In healthy physiological states, leukocytes like neutrophils have a short lifespan and undergo spontaneous apoptosis to prevent the release of toxic intracellular contents, such as proteases and reactive oxygen species, into surrounding tissues (PubMed: 1). Dysregulation of this process is a hallmark of various pathologies; for instance, delayed apoptosis contributes to chronic inflammatory conditions like rheumatoid arthritis and systemic lupus erythematosus, while excessive apoptosis can lead to immunosuppression in sepsis (PubMed: 7, 12). Although 'Leukocyte apoptosis' is a biological process rather than a single molecular entity, it is tightly regulated by a network of proteins including the Bcl-2 family (e.g., Mcl-1, Bax), caspases, and death receptors such as Fas (CD95) and TRAIL receptors (PubMed: 4, 10). Therapeutic strategies often focus on modulating these specific molecular regulators to either induce apoptosis in overactive immune cells or preserve leukocyte survival during acute injury (PubMed: 2, 4).

Other names

Neutrophil apoptosisLymphocyte apoptosisGranulocyte apoptosisImmune cell apoptosisWhite blood cell programmed cell death

Leukocyte apoptosis is modulated via the extrinsic pathway, triggered by death receptor ligation (e.g., FasL/Fas or TRAIL/TRAIL-R), and the intrinsic pathway, governed by mitochondrial outer membrane permeabilization (MOMP) and the balance of pro- and anti-apoptotic Bcl-2 proteins (PubMed: 1, 10). Drugs like glucocorticoids induce apoptosis by suppressing survival signals such as NF-κB and Mcl-1, while targeted therapies like venetoclax inhibit Bcl-2 to directly trigger the intrinsic apoptotic cascade in leukocytes (Blood: 3, MDPI: 4).